DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO; TASE) today announced that it has launched the store brand equivalent of over-the-counter ("OTC") Voltaren® Arthritis Pain (diclofenac sodium topical gel, 1%) to its retail partners and the product is now available in the U.S. nationwide. Perrigo's abbreviated new drug application ("ANDA") for OTC diclofenac sodium topical gel, 1% is the first store brand ANDA to receive approval from the U.S. Food and Drug Administration.
DUBLIN, Aug. 11, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, today announced that it will acquire three Eastern European OTC skincare and hair loss treatment brands (Emolium®, Iwostin® and Loxon®) from Sanofi. Trailing twelve months net sales ending June 30, 2020 for these products were approximately €21 million or approximately $23 million*. Other terms of the transaction were not disclose
DUBLIN, June 19, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced that it has reached a definitive agreement to sell its U.K.-based Rosemont Pharmaceuticals business, a generic prescription pharmaceuticals manufacturer focused on liquid medicines, to a U.K.-headquartered private equity firm for £156 million or approximately $195 million in cash. This transaction, which was signed and closed on the same day, represents another step in Perrigo's transformation to a consumer-focused self-care company.
DUBLIN, June 17, 2020 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today that it is entering the cannabidiol ("CBD") market through a strategic investment in and long-term supply agreement with Kazmira LLC, a leading supplier of hemp-based CBD products free of tetrahydrocannabinol ("THC-free") based in Watkins, Colorado. The fast-growing and rapidly evolving CBD market is emerging organically in response to changing consumer preferences for natural remedies and aligns with Perrigo's vision "To make lives better by bringing quality, affordable self-care products that consumers trust everywhere they are sold."
Perrigo is one of 36 companies and individuals named as defendants in the most recent complaint filed by various state attorneys general in relation to alleged antitrust violations within the generic pharmaceutical industry.
A year ago, we launched a new Diversity and Inclusion initiative for Perrigo that stressed the importance of having all members of our community treated with fairness and respect.
Allegan, Michigan and Bronx, New York – April 14, 2020 – Perrigo Company plc is responding to the urgent needs of hospital, medical and first responder personnel who are running dangerously low on medical supplies. Over the next few months, the Company will donate at least 500,000 bottles of hand sanitizer to local hospitals and first responders facing urgent shortages of this essential product.
DUBLIN, Ireland and Allegan, Michigan – April 7, 2020 – Perrigo Company plc and the Perrigo Company Charitable Foundation are donating $400,000 in funding and $216,000 in product donations to assist community partners who are essential to the COVID-19 response effort. Perrigo acted quickly to address the urgent need.
Perrigo Company plc is operating in an unprecedented time for our organization and for the world at large. As we see COVID-19 continue to spread across the countries in which we live and operate, we are mindful that Perrigo has a unique role in this historical situation as the provider of many of the remedies that millions of people are relying on to keep themselves and their families well, to treat their symptoms or ailments, and to help them recover when they fall ill.
Dublin, Ireland and Somerset, N.J. – February 25, 2020 – Perrigo Company plc (NYSE; TASE: PRGO) and its partner, Catalent Pharma Solutions, today announced that the U.S. Food and Drug Administration (FDA) has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA*. Perrigo is launching a limited quantity of generic albuterol sulfate inhalation aerosol and, in collaboration with its development and manufacturing partner Catalent, is ramping up production to meet future demand.
If you are a member of the press on deadline, please reach out to a member of our Global Investor Relations & Corporate Communications team.